Advertisement: Wild Knight Vodka
Advertisement: TTP
Barr Ellison Solicitors – commercial property
Advertisement: Kao Data Centre mid banner
Advertisement: Excalibur Healthcare mid banner
Mid banner advertisement: BDO
ARM Innovation Hub
Advertisement: CJBS mid banner
Advertisement: partnersand mid banner
Advertisement: RSM mid banner
Advertisement: Cambridge Network mid banner
Advertisement: HCR Hewitsons recruitment mid banner
Advertisement: S-Tech mid banner 3
Advertisement: Mogrify mid banner
Advertisement: EBCam mid banner
Advertisement: Simpsons Creative
3 November, 2021 - 19:19 By Tony Quested

o2h Ventures targets £1.5m SEIS Fund top-up

Cambridge star maker o2h Ventures is topping up its SEIS Fund with what it hopes will be a further £1.5 million raise.

Headed up by serial life science entrepreneur Sunil Shah, o2h has two funds – the o2h Ventures flagship knowledge-intensive EIS fund and the o2h Human Health SEIS Fund. 

Following the successful close of its flagship knowledge-intensive EIS fund on October 31 o2h has already executed the first deal from this into In4Derm. Now it moves on again.

The new fund has a closing date of November 7 and is targeting a significant or full deployment by end of the tax year with a portfolio spread across a minimum of five companies.

The o2h human health SEIS fund has a minimum investment Subscription of £10,000 and will invest in seed stage SEIS qualifying companies covering novel drug discovery along with enabling services, tools and AI technologies that can impact human health.

Shah said: “The geographic scope will be UK-wide but will target the growing Cambridge biotech cluster which is now the global headquarters of AstraZeneca and is home to many biotech companies – some of which have subsequently been snapped up by large pharmaceutical companies.”

Newsletter Subscription

Stay informed of the latest news and features